Caisse DE Depot ET Placement DU Quebec increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,352 shares of the biotechnology company’s stock after acquiring an additional 900 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Biogen were worth $14,889,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in BIIB. Assenagon Asset Management S.A. bought a new position in Biogen during the third quarter valued at about $123,494,000. Botty Investors LLC raised its holdings in Biogen by 75.0% during the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock valued at $3,048,000 after buying an additional 4,812 shares in the last quarter. BB&T Securities LLC raised its holdings in Biogen by 25.0% during the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock valued at $3,524,000 after buying an additional 2,598 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in Biogen by 18.6% during the second quarter. Neuberger Berman Group LLC now owns 27,974 shares of the biotechnology company’s stock valued at $7,591,000 after buying an additional 4,389 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its holdings in Biogen by 9.6% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 5,948 shares of the biotechnology company’s stock valued at $1,862,000 after buying an additional 520 shares in the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.
In other news, Director Alexander J. Denner bought 30,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was bought at an average price of $317.36 per share, for a total transaction of $9,520,800.00. Following the completion of the purchase, the director now owns 10,029 shares of the company’s stock, valued at approximately $3,182,803.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.25% of the company’s stock.
Biogen Inc. (NASDAQ:BIIB) opened at $314.66 on Thursday. Biogen Inc. has a one year low of $244.28 and a one year high of $348.84. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46. The stock has a market cap of $67,122.77, a P/E ratio of 14.70, a PEG ratio of 1.98 and a beta of 0.73.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the company posted $5.19 earnings per share. Biogen’s quarterly revenue was up 4.1% compared to the same quarter last year. sell-side analysts forecast that Biogen Inc. will post 22.03 EPS for the current fiscal year.
Several research firms have weighed in on BIIB. Oppenheimer set a $350.00 target price on Biogen and gave the company a “buy” rating in a report on Monday. BMO Capital Markets reiterated a “buy” rating and issued a $385.00 price objective on shares of Biogen in a research note on Monday, November 27th. Sanford C. Bernstein set a $318.00 price objective on Biogen and gave the stock a “buy” rating in a research note on Tuesday, November 28th. J P Morgan Chase & Co set a $378.00 price objective on Biogen and gave the stock a “buy” rating in a research note on Monday, November 27th. Finally, Mizuho set a $400.00 price objective on Biogen and gave the stock a “buy” rating in a research note on Monday, November 27th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $344.60.
ILLEGAL ACTIVITY WARNING: “Caisse DE Depot ET Placement DU Quebec Purchases 900 Shares of Biogen Inc. (BIIB)” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thestockobserver.com/2017/12/07/caisse-de-depot-et-placement-du-quebec-purchases-900-shares-of-biogen-inc-biib.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.